Cara Therapeutics Inc. shares CARA, -1.74% soared 34% in premarket trade Wednesday, after the company reported positive data in a Phase 2/3 trial of a treatment for pain in patients undergoing abdominal surgery. Cara said the trial of I.V. CR845 at the 1.0 mcg/kd dose demonstrated statistically significant reduction in pain intensity compared with placebo in the trial that involved 228 patients who underwent ventral hernia surgery and 216 patients who had a hysterectomy. The treatment also succeeded in reducing nausea and vomiting after surgery. "As there continues to be a critical need for new post-surgical analgesics like I.V. CR845 that lack abuse potential and traditional mu opioid side effects, we will be assessing all options, including discussions with regulators, as to how to best move this program forward," Cara Chief Executive Derek Chalmers said in a statement. The company will host a conference call at 8.30 a.m. Eastern. Shares gained 34.3% in 2018 through Tuesday, while the S&P 500 SPX, +1.26% has gained 1.9%.